Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cyto.b.22214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
fusion gene in hematological neoplasms: clinical features, current practices, and prognoses.
Hematology
December 2024
Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Introduction: -, formerly , is a rarely reported fusion gene in hematological malignancies, especially in Asian people.
Case Presentations: Six patients with fusion gene were identified at the First Affiliated Hospital, Zhejiang University School of Medicine, China between October 2019 and October 2023, with a median age of 25 years. Clinical diagnoses included acute myeloid leukemia (AML) in 2 patients, acute lymphoblastic leukemia (ALL) in 3, and mixed phenotype acute leukemia (MPAL) in 1.
[PICALM-MLLT10 fusion gene positive with multiple gene mutations in a child with T-lymphoblastic lymphoma/leukemia: a case report].
Zhonghua Xue Ye Xue Za Zhi
April 2024
Pediatric Hematology and Oncology Department, the Affiliated Hospital of Qingdao University, Qingdao 266000, China.
RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification.
Cancer Med
April 2023
Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
Background: Myeloid sarcoma (MS) is a rare, extramedullary tumor consisting of myeloid blasts. Little is known about the genetic background of MS and the prognostic value of genetic abnormalities in MS. In particular, the broad variety of gene fusions that occur in MS is marginally covered by traditional testing methods due to lack of fresh tumor specimens.
View Article and Find Full Text PDFThe First Case of Acute Myeloid Leukemia With t(10;11)(p13;q21); Rearrangement Presenting With Extensive Skin Involvement.
Ann Lab Med
May 2023
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins.
Blood Cancer J
January 2022
Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.
T-cell acute lymphoblastic leukemias (T-ALL) represent 15% of pediatric and 25% of adult ALL. Since they have a particularly poor outcome in relapsed/refractory cases, identifying prognosis factors at diagnosis is crucial to adapting treatment for high-risk patients. Unlike acute myeloid leukemia and BCP ALL, chromosomal rearrangements leading to chimeric fusion-proteins with strong prognosis impact are sparsely reported in T-ALL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!